Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tvardi Therapeutics (TVRD) Net Cash Flow (2016 - 2025)

Tvardi Therapeutics' Net Cash Flow history spans 13 years, with the latest figure at -$684000.0 for Q4 2025.

  • On a quarterly basis, Net Cash Flow fell 102.52% to -$684000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $9.6 million, a 83.37% decrease, with the full-year FY2025 number at -$10.9 million, down 118.94% from a year prior.
  • Net Cash Flow hit -$684000.0 in Q4 2025 for Tvardi Therapeutics, down from $770000.0 in the prior quarter.
  • Over the last five years, Net Cash Flow for TVRD hit a ceiling of $39.6 million in Q2 2024 and a floor of -$16.3 million in Q1 2023.
  • Historically, Net Cash Flow has averaged $4.4 million across 5 years, with a median of $236000.0 in 2021.
  • The widest YoY moves for Net Cash Flow: up 13880.43% in 2022, down 696.34% in 2022.
  • Tracing TVRD's Net Cash Flow over 5 years: stood at -$9.5 million in 2021, then skyrocketed by 319.49% to $20.9 million in 2022, then plummeted by 153.02% to -$11.1 million in 2023, then surged by 344.83% to $27.2 million in 2024, then plummeted by 102.52% to -$684000.0 in 2025.
  • Business Quant data shows Net Cash Flow for TVRD at -$684000.0 in Q4 2025, $770000.0 in Q3 2025, and $13.2 million in Q2 2025.